SUNNYVALE, Calif., April 25, 2025 /PRNewswire/ – Willow Biosciences Inc. (“Willow” or the “Company“) (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general and special meeting of shareholders held on April 25, 2025 (the “Meeting“). A total of 59,214,893 common shares, representing approximately 40.88% of the Company’s issued and outstanding shares were represented at the meeting.
The shareholders approved the setting of the number of directors of Willow at 5 directors, and the following nominees were elected as directors of Willow for the ensuing year with the specific voting results being as follows:
|
Votes For |
Votes Withheld |
|||
|
Director |
# |
% |
# |
% |
|
Dr. Chris Savile |
46,902,346 |
88.3 % |
6,234,676 |
11.7 % |
|
Dr. Jim Lalonde |
46,965,380 |
88.4 % |
6,171,642 |
11.6 % |
|
Donald Archibald |
44,900,287 |
84.5 % |
8,236,735 |
15.5 % |
|
Raffi Asadorian |
46,963,057 |
88.4 % |
6,173,965 |
11.6 % |
|
Al Foreman |
46,900,723 |
88.3 % |
6,236,299 |
11.7 % |
In addition, shareholders approved the below matters. The resolutions approving the below matters may be viewed in full in the Company’s management information circular dated March 26, 2025 (the “Information Circular“).
|
Votes For |
||
|
Director |
# |
% |
|
Appointment of KPMG LLP as the Company’s auditor for the ensuring year |
51,882,364 |
87.6 % |
|
The proposed sale of the shares of Epimeron USA, Inc., the Corporation’s |
46,996,397 |
88.4 % |
|
To authorize the Corporation’s board of directors, at its sole discretion, to |
48,853,362 |
82.5 % |
For complete voting results on all matters approved at the Meeting, please see the Company’s Report of Voting Results dated April 25, 2025, available on SEDAR+ at www.sedarplus.ca.
About Willow Biosciences Inc.
Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow’s FutureGrownTM biotechnology platform allows large-scale production with sustainability at its core. Willow’s R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers.
For more information, visit www.willowbio.com or contact:
Travis Doupe
Chief Financial Officer
E: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/willow-biosciences-announces-annual-general-and-special-meeting-voting-results-302438831.html
SOURCE Willow Biosciences Inc.
Featured Image: Unsplash @ brookelark
